盐酸去氧肾上腺素(Phenylephrine Hydrochloride) - 药物靶点：ADRA1_在研适应症：麻醉，瞳孔散大，低血压_专利_临床

概要

基本信息

简介苯肾上腺素是一种小分子药物，其作用为α-1肾上腺素能受体激动剂。它主要用于扩张眼瞳以进行眼科检查和手术。通过与虹膜扩张肌中的α-1肾上腺素受体结合，苯肾上腺素盐酸盐引起肌肉收缩，导致瞳孔扩张。这种药物通常用于眼科诊断，例如检查视网膜或测量眼内压。苯肾上腺素盐酸盐以滴眼剂的形式局部给药，通常在10到20分钟内起效，扩张效果可持续数小时

药物类型

小分子化药

别名

(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol、Phenylephrine、Phenylephrine hydrochloride (JP17/USP)

+ [21]

靶点

ADRA1

作用方式

激动剂

作用机制

ADRA1激动剂(肾上腺素能受体α-1家族激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Paragon BioTeck, Inc.

Exela Pharma Sciences LLCAlcon Research LLC

+ [5]

非在研机构

Applied Biology, Inc.

RDD Pharma Ltd.

S.L.A. Pharma AG

+ [1]

权益机构

Dr. Reddy's Laboratories Ltd.

Eton Pharmaceuticals, Inc.Dr. Reddy's Laboratories SA

+ [3]

最高研发阶段批准上市

首次获批日期

日本 (1954-10-11),

低血压休克心动过速

最高研发阶段(中国)批准上市

特殊审评孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C9H13NO2

InChIKeySONNWYBIRXJNDC-VIFPVBQESA-N

CAS号59-42-7

查看全部结构式(2)

关联

358

项与盐酸去氧肾上腺素相关的临床试验

NCT06158035

/ Not yet recruitingN/AIIT

ED90 of Norepinephrine and Phenylephrine Boluses for Treating Postspinal Anesthesia Hypotension Under Intensive Treatment in Preeclamptic Patients During Cesarean Section

The objective of this study is to investigate the ED90 of norepinephrine and phenylephrine boluses for treating postspinal anesthesia hypotension under intensive treatment in preeclamptic patients during cesarean section

开始日期2025-07-01

申办/合作机构

宁夏医科大学总医院

NCT06151470

/ Not yet recruitingN/AIIT

90% Effective Dose of Phenylephrine Infusions for Preventing Postspinal Anesthesia Hypotension Under Intensive and Standard Treatment in Preeclamptic Patients During Cesarean Section

The objective of this study is to investigate the 90% effective dose of phenylephrine infusions for preventing postspinal anesthesia hypotension under intensive and standard treatment in preeclamptic patients during cesarean section

开始日期2025-07-01

申办/合作机构

宁夏医科大学总医院

CTRI/2025/04/084743

/ Not yet recruiting临床3期IIT

Evaluation of varying weight based doses of continuous phenylephrine infusion for prevention of hypotension in patients undergoing cesarean section under spinal anesthesia-A Prospective Randomised Double Blinded Study. - Nil

开始日期2025-06-05

申办/合作机构-

100 项与盐酸去氧肾上腺素相关的临床结果

登录后查看更多信息

100 项与盐酸去氧肾上腺素相关的转化医学

登录后查看更多信息

100 项与盐酸去氧肾上腺素相关的专利（医药）

登录后查看更多信息

24,054

项与盐酸去氧肾上腺素相关的文献（医药）

2025-07-01·European Journal of Pharmacology

Melatonin induces urethral contraction and increases intraurethral pressure via MT1 receptor activation in female rats

Article

作者: Yanai-Inamura, Hiroko ; Kajiro, Masashi ; Yokono, Masanori ; Tanahashi, Masayuki ; Matsui, Shigeo ; Takamatsu, Hajime

Melatonin is released by the pineal gland and exerts numerous physiological effects via specific G protein-coupled receptors named MT₁ and MT₂ receptors. It is well known that melatonin acts as a key regulator of circadian rhythm through the activation of these receptors on the central nervous system. However, the expression and function of melatonin receptors in the lower urinary tract remain unclear. This study aimed to investigate the expression and function of melatonin receptors in female urethra. mRNA expression analysis exhibited high expression of MT₁ and MT₂ receptor mRNA in human and rat female urethra. A study of isolated female rat urethral tissue strips using melatonin receptor agonists and an antagonist strongly revealed that stimulation of melatonin MT₁ receptor induced urethral smooth muscle contraction. Further investigation of the mechanism underlying this melatonin MT₁ receptor-related urethral contraction demonstrated that stimulation of MT₁ receptors in urethra activates intracellular Ca²⁺ mobilization via G_q protein-dependent pathways, resulting in smooth muscle contraction. In vivo studies also revealed that melatonin receptor agonists induced an increase in urethral perfusion pressure in female rats. This is the first study to clearly demonstrate the expression and function of melatonin receptors in the urethra. These findings suggested that activation of MT₁ receptors could be a potential pharmacological target for modulation of urethral function.

2025-06-01·Pharmacology Biochemistry and Behavior

Monoamine receptors targeted by methamphetamine differentially modulate basal and fentanyl-depressed respiration in mice

Article

作者: Walentiny, D Matthew ; Elder, Harrison J ; Beardsley, Patrick M

RATIONALEFentanyl remains the primary cause of fatal overdoses, and its co-use with methamphetamine is a growing concern. Our lab previously demonstrated that racemic methamphetamine could have either respiratory stimulant or depressant effects depending on dose and separately determined by its enantiomers, dextromethamphetamine, and levomethamphetamine, respectively. Enantiomeric separation of methamphetamine's stimulant and depressant effects indicates that differences in their pharmacology might be exploited to develop novel respiratory stimulants. It is presently unknown which of methamphetamine's monoamine receptor mechanisms mediate these respiratory effects. Thus, systematic evaluation of monoamine receptor-selective agents may identify treatment targets for OIRD.METHODSSix selective agonists at monoamine receptors involved in methamphetamine's activity [phenylephrine (PNE; α₁), clonidine (CLON; α₂), SKF-82958 (SKF; D₁), quinpirole (QPR; D₂-like), 8-OH-DPAT (8-OH; 5HT_1A), and DOI (5HT₂)] were tested in adult male mice to determine their effects on basal and fentanyl-depressed minute volume (MVb; i.e., respiratory frequency x tidal volume) using whole-body plethysmography. Agonists were initially tested at three behaviorally active doses for their effects on basal MVb. Agonists that stimulated respiration or did not decrease respiration were then tested in combination with fentanyl.RESULTSThe α₁ and D₁ agonists PNE and SKF dose-dependently increased basal MVb while the α₂ and D₂-like agonists CLON and QPR depressed basal MVb. Neither serotonin receptor agonist significantly altered basal MVb. Under fentanyl-depressed conditions, SKF produced transient but significant increases in MVb, while PNE more persistently elevated it. Interestingly, DOI transiently elevated depressed MVb, while 8-OH further exacerbated OIRD.CONCLUSIONSSelective activation of monoamine receptors alters basal respiration and OIRD, with D₁ and α₁ receptors representing potential targets as respiratory stimulants, whereas α₂, D₂-like, and 5HT_1A receptors may mediate the exacerbation of OIRD by methamphetamine.

2025-06-01·European Journal of Pharmacology

The sodium-glucose cotransporter 2 inhibitor tofogliflozin induces vasodilation of rabbit femoral artery by activating Kv channels, the SERCA pump, and the sGC/cGMP pathway

Article

作者: Kim, Hye Ryung ; An, Jin Ryeol ; Jung, Won-Kyo ; Seo, Mi Seon ; Jeong, Junsu ; Park, Minju ; Park, Hongzoo ; Jang, YeEun ; Park, Won Sun ; Zhuang, Wenwen ; Choi, Il-Whan

Tofogliflozin is a sodium-glucose cotransporter 2 inhibitor widely used to treat type 2 diabetes mellitus, but it also exhibits cardio-protective effects. This study investigated the vasodilatory action of tofogliflozin using rabbit femoral artery rings pre-contracted with phenylephrine (1 μM). The results showed the concentration-dependent induction of vasodilation by tofogliflozin, a response that remained unchanged following endothelial removal, pretreatment with the nitric oxide synthase inhibitor L-NAME (100 μM), or the inhibition of low- and intermediate-conductance Ca²⁺-activated K⁺ channels using apamin (1 μM) in combination with TRAM-34 (1 μM). Furthermore, pretreatment with the voltage-dependent K⁺ (Kv) channel inhibitor 4-AP (3 mM) reduced the vasodilatory effects of tofogliflozin whereas pretreatment with the ATP-sensitive K⁺ channel inhibitor glibenclamide (10 μM) or the large-conductance Ca²⁺-activated K⁺ channel inhibitor paxilline (1 μM) did not. Notably, our findings indicated that Kv7.X, rather than Kv1.5 or Kv2.1, is the primary Kv subtype involved in tofogliflozin-induced vasodilation. The vasodilatory effects of tofogliflozin were also significantly inhibited in femoral arterial rings pretreated with the sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) pump inhibitors thapsigargin (1 μM) and cyclopiazonic acid (10 μM). Tofogliflozin-induced vasodilation was unaltered in arterial rings exposed to the adenylyl cyclase inhibitor SQ 22536 (50 μM), the protein kinase A (PKA) inhibitor KT 5720 (1 μM), and the protein kinase G inhibitor KT 5823 (1 μM) whereas it was effectively reduced by the soluble guanylyl cyclase (sGC) inhibitor ODQ (10 μM). These findings suggest that tofogliflozin-induced vasodilation is mediated by the activation of the SERCA pump, the sGC/cGMP pathway, and Kv channels.

276

项与盐酸去氧肾上腺素相关的新闻（医药）

2025-04-23

·PRNewswire

ProRx Pharma Continues to Expand Preventative Health Portfolio with Six New Products

Expanded Product Line Targets Growing Demand for Proactive Wellness Solutions in Clinics, Med Spas, 503A Pharmacies, and Telehealth Practices Across the United States WEST PALM BEACH, Fla. and EXTON, Pa., April 23, 2025 /PRNewswire/ -- ProRx Pharma, the leading health and wellness 503B outsourcing facility, today announced the addition of six new injectable products designed to support the rising demand for preventive care: Gonadorelin, Liraglutide, Vitamin D3, and Phenylephrine HCl as well as two Tri-Mix injection options. These high-quality standalone injectables are now available for bulk shipping to licensed medical facilities in 26 states and for direct-to-consumer shipping nationwide through ProRx's growing network of 503A pharmacies, clinics, med spas and telehealth providers. "Patients are taking charge of their health like never before," said Kurt Lunkwitz, chief operating officer at ProRx. "Physicians are following suit, integrating wellness therapies into their practices to meet the demand for more proactive, functional care. This trend is only going to continue. The continued expansion of our health and wellness line is a direct response—and a step toward making preventative health more accessible and streamlined." What's New: The Products Each of the six new offerings comes with its own National Drug Code (NDC) number and an extended Beyond Use Date (BUD), providing both flexibility and longer shelf life for providers: Gonadorelin ( 1 mg/mL, 6 mg / 6 mL vial ) A gonadotropin-releasing hormone agonist which is used in fertility medicine and to treat amenorrhea and hypogonadism. Gonadorelin may promote testosterone production; may support fertility, libido, and hormonal balance. Liraglutide ( 0.75 mg, 1 mg, 2 mg, 3 mg [custom dosing] ) A powerful GLP-1 receptor agonist for weight and blood-sugar management. Liraglutide may aid in weight loss, appetite suppression, and blood-sugar control. Vitamin D3 ( 50,000 IU/mL, 5 mL vial ) A high-dose solution for those with critically low vitamin D levels. Vitamin D3 may support immune function, bone health, mood, and Vitamin D repletion. Tri-Mix #1 ( 30 mg / 1 mg / 10 mcg/mL, 5 mL vial ) The first of two strength offerings for erectile dysfunction (ED) therapy. Tri Mix #1 may improve erectile response through smooth muscle relaxation and blood flow. Tri-Mix #2 ( 30 mg / 2 mg / 20 mcg/mL, 5 mL vial ) A stronger ED therapy offering. Tri-Mix #2, may provide more ED support for patients needing increased vasodilation. Phenylephrine HCl ( 0.1% 2 mL vial) A critical safety solution for patients using Tri-Mix therapies. Phenylephrine HCl may reverse prolonged erection or priapism due to ED therapy. The introduction of these six new products comes on the heels of ProRx announcing its first four preventative-care offerings the first week of April: Sermorelin, NAD+, Glutathione and MIC/B6/B12. Exclusive Launch at A4M Conference ProRx is showcasing its full line of preventative-care products at the A4M 33rd Annual Spring Conference taking place April 24-26 in West Palm Beach, Florida. At Booth 527, attendees will get an exclusive first look at all 10 products in the new product line and be able to speak with ProRx's experts about the company's compliance and quality-assurance programs. About ProRx Pharma ProRx Pharma is an FDA-registered cGMP facility focused on providing essential compounded medications to meet the need for medications on the FDA drug shortage and bulks list with an emphasis on preventative health. The company produces products and formulations for medical institutions, physician offices, and 503A pharmacies, with a specialization in producing high-quality products to ensure patients have access to the medications they need during critical shortages. For more information, visit SOURCE ProRx Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2025-03-27

·SYNAPSE

Eyenovia proposes merger with Betaliq to form glaucoma company

Eyenovia, Inc. and Betaliq, Inc. could potentially be heading toward a “reverse merger transaction” to form a new ophthalmic company, the companies recently announced. We’ll start with Eyenovia. Based in New York, the commercial-stage ophthalmic pharmaceutical technology company is developing a pipeline of micro-dosed treatments for front-and-back-of-eye diseases, including presbyopia, mydriasis, and myopia. On the regulatory side: The company’s Mydcombi (tropicaide and phenylephrine hydrochloride ophthalmic spray) 1% / 2.5% for inducing mydriasis was cleared by the FDA in 2023. The Optejet device is exclusively designed for ocular therapeutics as a way to dispense topical eye medications using Eyenovia’s Microdose Array Print (MAP) technology as a topical delivery system (similar to an inkjet printer). The process: Medication is dispensed horizontally in a mist to coat the surface of the cornea, with contact to the eye occurring at a low velocity to reduce ocular impact. The glaucoma-focused, clinical-stage pharmaceutical company—launched via a collaboration with Novaliq GmbH—is developing a portfolio of topical glaucoma treatments featuring a unique delivery system of its own. Eyenovia entered into a non-binding LOI with Betaliq to consider a reverse merger transaction to create a new ophthalmic company focused on the aforementioned proprietary technologies. Its proposed therapeutic focus: glaucoma. While both the Optejet and EyeSol platforms provide similar benefits for enhancing products’ ease of use and compliance with therapeutics, the companies also noted that—most importantly—EyeSol is compatible with the Optejet. Plus: EyeSol delivers a 10 microliters (µL) drop size that can be replicated in the Optejet device. There is, actually. Per the companies, the value for each—assuming zero cash (net of liabilities) at the closing of this potential merger—would be: For equity holders: As a result of this exchange ratio, the intent would be for Betaliq and Eyenovia equity holders to own an estimated 83.7% and 16.3% of the newly-combined company, respectively. Eyenovia CEO Michael Rowe stated that a potential merger is “in the best interests of our company, our team members, patients, and shareholders.” Similarly: Betaliq CEO Barry Butler emphasized the “significant opportunity in the eyecare space” that the joining of both technologies could represent for patients with glaucoma and other ocular diseases—not to mention opportunities for pipeline expansion. No exact timeframe has been shared so far. Even further: The deal will be contingent on a number of factors and definitive agreements from both sides. There are! Eyenovia plans to file for U.S. regulatory approval of a user-filled version of the Optejet, designed to operate with a number of topical ophthalmic liquids such as artificial tears and rewetting products. So on both fronts—this merger and the user-filled Optejet—stay tuned for news!

2025-03-27

·米内网

第十一批国采54个超“卷”品种备战！448亿市场倍特、齐鲁蓄力，13个超10亿大品种或承压

精彩内容近日，有消息称，第十一批国采在规则上或有变化。米内网数据显示，截至3月25日，已有100余个品种满足国采入围门槛，其中有54个符合申报资格企业数（以集团计）达10家及以上，448亿市场波澜欲起，倍特、华润、科伦、石四药、齐鲁等蓄势待发。符合申报资格企业数≥10家且暂未纳入国采的品种（详细表格见文末）注：部分药品因专利期、产品属性等可能不会被纳入集采，一切信息以官方为准！手工整理，如有疏漏，欢迎指正。来源：米内网综合数据库 13个超10亿大品种！448亿市场激战在即从销售额看，54个品种2023年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售规模合计接近448亿元。超10亿大品种有13个，占比约24%；超过5亿元但低于10亿元的品种有14个，占比约26%；超过1亿元但不足5亿元的品种有20个，占比约37%；低于1亿元的品种有7个，占比约13%。 54个品种销售额分布情况从治疗领域看，54个品种涵盖11个治疗大类，集中在血液和造血系统药物、消化系统及代谢药、呼吸系统用药，分别有11个、10个、9个品种在列，占比均超过10%。米内网数据显示，上述3个治疗大类2023年在中国公立医疗机构终端的销售额分别超过1100亿元、1200亿元、460亿元。 54个品种治疗大类分布情况从剂型分布看，54个品种中有20个为口服常释剂型，占比约37%；注射剂、口服液体剂则分别有14个、12个，占比均超过20%。在2023年中国公立医疗机构化学药终端，注射剂、口服液体剂销售额分别超过4400亿元、230亿元。 54个品种剂型分布情况 “卷王”之战！7大品种达25家以上从竞争情况看，54个品种中，有7个品种符合申报资格企业数超过25家，4个品种在20-24家之间，14个品种在15-19家之间，29个品种在10-14家之间。 54个品种竞争情况乳果糖口服液体剂为最“卷”品种，目前符合申报资格企业数已达31家；此外，法莫替丁注射剂、二羟丙茶碱注射剂、氨溴特罗口服液体剂均达29家，氨溴索口服液体剂达28家，头孢唑肟注射剂达27家，乙酰半胱氨酸吸入剂达26家，地氯雷他定口服液体剂、达格列净口服常释剂型均达23家，米诺地尔外用液体剂达22家，沙库巴曲缬沙坦口服常释剂型达21家。乳果糖口服液体剂是一款渗透性泻药，为全国医保乙类、OTC甲类（双跨）品种，2023年在中国公立医疗机构终端的销售额超过17亿元，在治疗便秘的化药产品排名中稳居首位。从厂家格局看，雅培（原研）、韩美（已过评）、费森尤斯卡比依次位列前三，市场份额均超过10%。目前国内已有31家药企（以企业名称计）的乳果糖口服溶液获批生产并视同过评，此外还有30余家企业的产品以新注册分类报产在审，竞争激烈。近年来中国公立医疗机构终端乳果糖口服液体剂销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局法莫替丁注射剂为组胺H2受体阻滞剂，用于治疗与胃酸分泌相关疾病，目前已有29家药企的法莫替丁注射液过评或视同过评。米内网数据显示，近年来中国公立医疗机构终端法莫替丁注射剂市场有所承压，2023年销售额超过27亿元。从厂家格局看，山西威奇达光明制药（已过评）、江西赣南海欣药业（未过评）、开封康诺药业（未过评）依次位列前三，市场份额均超过10%。近年来中国公立医疗机构终端法莫替丁注射剂销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局 10个及以上！倍特、科伦、石四药蓄力从企业层面看，倍特药业、科伦药业、华润医药、福安药业、江苏万高药业、石家庄四药、齐鲁制药、山东京卫制药、新和成均有10个以上的品种在列。有10个以上品种在列的集团倍特药业有15个品种在列，包括6个口服常释剂型、4个口服液体剂、3个注射剂及2个吸入剂。有13个品种以新分类报产获批而视同过评，其中瑞巴派特片、盐酸去氧肾上腺素注射液、罗沙司他胶囊、富马酸福莫特罗吸入溶液、马来酸氟伏沙明片、达格列净片、盐酸丙卡特罗口服溶液、马来酸阿伐曲泊帕片为2024年新获批上市的品种。科伦药业有15个品种在列，包括7个注射剂、6个口服常释剂型、1个外用液体剂及1个软膏剂。有9个品种以新分类报产获批而视同过评，艾曲泊帕乙醇胺片、马来酸阿伐曲泊帕片为2024年新获批上市的品种，罗沙司他胶囊、米诺地尔搽剂、利丙双卡因乳膏、阿戈美拉汀片为2025年新获批上市的品种。符合申报资格企业数≥10家且暂未纳入国采的品种资料来源：米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至3月25日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

专利到期带量采购

100 项与盐酸去氧肾上腺素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00511	盐酸去氧肾上腺素	C01CA06 R01BA03 S01FB01 S01GA05 R01AB01 R01AA04	DB00388

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	美国	Dr. Reddy's Laboratories SA	2019-10-21
瞳孔散大	美国	Paragon BioTeck, Inc.	2013-03-21
低血压	日本	Kowa Co., Ltd.	1954-10-11
休克	日本	Kowa Co., Ltd.	1954-10-11
心动过速	日本	Kowa Co., Ltd.	1954-10-11

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床3期	美国	University of Wisconsin Madison	2015-05-14
放射性口腔黏膜炎	临床3期	美国	University of Wisconsin	2015-05-14
移植并发症	临床3期	美国	University of Wisconsin Madison	2015-05-14
粘膜炎	临床3期	美国	University of Wisconsin Madison	2010-03-01
口腔炎	临床3期	美国	University of Wisconsin Madison	2010-03-01
大便失禁	临床3期	英国	S.L.A. Pharma AG	2007-02-01
血管迷走神经性晕厥	临床2期	美国	University of Wisconsin Madison	2021-07-20
生理性性功能障碍	临床前	美国	Applied Biology, Inc.	2018-07-09
心理性性功能障碍	临床前	美国	Applied Biology, Inc.	2018-07-09
尿失禁	临床前	以色列	RDD Pharma Ltd.	2009-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed \| Int J Obstet Anesth	N/A	-	-	phenylephrine (Intermittent pneumatic compression (IPC))	獵鏇製構齋憲鬱廠齋糧(獵憲艱夢衊艱鬱鬱醖繭) = 獵網鹹醖襯衊襯鑰艱夢醖築糧鹹憲鬱糧鑰膚鑰 (艱齋淵淵網衊觸簾遞鏇 )	积极	2024-11-01
				phenylephrine (Control (no IPC))	獵鏇製構齋憲鬱廠齋糧(獵憲艱夢衊艱鬱鬱醖繭) = 遞襯鹹廠網餘衊積窪構醖築糧鹹憲鬱糧鑰膚鑰 (艱齋淵淵網衊觸簾遞鏇 )
EURETINA2024 人工标引	N/A	-	53	Tropicamide + Phenylephrine hydrochloride	範艱製衊蓋窪醖膚獵壓(觸齋遞鏇衊網鹽築鹽鏇) = 願顧積製鹹糧網壓範鏇醖鏇廠構齋積膚簾遞鏇 (襯齋壓鹹遞壓餘夢淵鹽 ) 更多	积极	2024-09-19
NCT03849508 (Pubmed \| Anesth Analg)	临床4期	麻醉维持	124	Norepinephrine	積衊築糧鏇膚範範繭醖(夢壓夢繭鑰築齋蓋醖簾): ARD = -2.4 (95% CI, -4.4 ~ -0.5) 更多	积极	2022-10-24
				Phenylephrine
NCT05439460 (CTgov)	临床4期	肺动脉高压危象 \| 肺动脉高压	15	phenylephrine (Phenylephrine)	積製築網憲鹹憲鏇製鑰(鹹顧網網蓋襯鏇廠夢鏇) = 願襯顧餘醖選積餘網簾選觸觸構淵獵築鏇鹽築 (壓選製觸製鑰積窪獵蓋, 膚醖壓艱夢網廠餘積淵 ~ 蓋醖鬱鏇簾簾顧鑰獵鹹) 更多	-	2022-08-05
				Arginine Vasopressin (Arginine Vasopressin)	積製築網憲鹹憲鏇製鑰(鹹顧網網蓋襯鏇廠夢鏇) = 艱衊觸鹽顧艱衊遞膚夢選觸觸構淵獵築鏇鹽築 (壓選製觸製鑰積窪獵蓋, 鹹艱糧廠選範觸願遞壓 ~ 壓鏇鹹艱窪襯願積製鑰) 更多
NCT00458003 (CTgov)	N/A	子痫前症 \| 低血压	110	Phenylephrine (Phenylephrine)	製鏇窪襯齋醖糧衊憲鑰(鹹製範憲糧蓋鏇廠鹽襯) = 範簾衊鹽廠製壓遞糧衊蓋鹽構網築鏇醖齋遞淵 (構鬱鬱憲淵鹽鹽鬱壓範, 選鹹遞餘鬱膚製繭鏇齋 ~ 衊餘餘繭襯膚鹹淵膚簾) 更多	-	2022-06-02
				Ephedrine (Ephedrine)	製鏇窪襯齋醖糧衊憲鑰(鹹製範憲糧蓋鏇廠鹽襯) = 願夢餘鬱醖鏇艱選鹽顧蓋鹽構網築鏇醖齋遞淵 (構鬱鬱憲淵鹽鹽鬱壓範, 壓觸襯憲壓願艱鬱選鑰 ~ 蓋餘網網簾網積淵淵獵) 更多
ATS2022	N/A	心房颤动	-	Norepinephrine	(醖鹹憲糧觸窪網夢網膚) = 膚襯淵築顧獵膚觸範築遞網鹹淵餘蓋獵築憲膚 (鹽齋獵鏇鹹繭糧築築壓, -5 ~ -1)	-	2022-05-15
				Phenylephrine	(醖鹹憲糧觸窪網夢網膚) = 艱窪淵願繭鏇繭壓觸淵遞網鹹淵餘蓋獵築憲膚 (鹽齋獵鏇鹹繭糧築築壓, -7 ~ -2)
NCT02025426 (CTgov)	临床4期	先兆子痫	13	Phenylephrine (Phenylephrine)	鑰鹽願壓蓋選願餘憲獵(願糧襯膚製壓憲醖網鏇) = 製夢繭製餘觸遞窪齋製窪艱觸襯襯遞選製願簾 (鑰蓋網顧膚積鹹鑰蓋餘, 鹹衊衊鬱醖簾願顧襯積 ~ 顧製鬱鬱艱襯齋遞選構) 更多	-	2020-10-14
				Ephedrine (Ephedrine)	鑰鹽願壓蓋選願餘憲獵(願糧襯膚製壓憲醖網鏇) = 壓齋繭廠餘糧鬱餘遞壓窪艱觸襯襯遞選製願簾 (鑰蓋網顧膚積鹹鑰蓋餘, 廠鏇壓願選齋鹹鬱糧選 ~ 壓醖壓醖鹹餘範顧壓淵) 更多
ChiCTR-IPR-15006235 (Pubmed \| Br J Anaesth)	临床4期	麻醉	668	Norepinephrine	鏇醖憲鑰淵願夢積醖鏇(蓋淵繭鬱製築艱廠衊築) = 壓製膚艱鹽遞觸衊憲齋廠窪廠壓顧艱膚憲繭製 (製淵膚窪鏇獵鑰願築網 )	积极	2020-07-15
				Phenylephrine	鏇醖憲鑰淵願夢積醖鏇(蓋淵繭鬱製築艱廠衊築) = 窪齋鹽憲餘餘構網壓遞廠窪廠壓顧艱膚憲繭製 (製淵膚窪鏇獵鑰願築網 )
NCT02132312 (Pubmed \| J Cataract Refract Surg) 人工标引	临床3期	疼痛	72	phenylephrine +ketorolac	(憲鹽顧鬱積糧窪繭糧蓋) = There were no notable changes in vital signs or ophthalmological complications in either group. 簾製糧鹹淵顧積製憲餘 (範簾艱製艱齋壓鬱構鑰 ) 更多	积极	2020-06-01
				phenylephrine (PE) 1.0%
AUA2020	N/A	阴茎异常勃起	110	Intracavernosal injection of phenylephrine (PE)	夢製範憲觸簾齋鹹遞範(醖憲構獵淵範鏇襯膚鹽) = 獵夢窪選鑰製簾壓醖衊廠膚網餘製觸繭積夢築 (繭選醖襯願壓觸淵築壓 )	-	2020-04-01